Sanofi’s Lemtrada MS Drug Effective in Extension Trial

Sanofi, France’s biggest drugmaker, said its experimental medicine Lemtrada remained effective in patients suffering from multiple sclerosis during the first year of an extension study.

Relapse rates and sustained accumulation of disability remained low among patients who had been administered the treatment in previous clinical trials, Paris-based Sanofi said in an e-mailed statement today. More than 80 percent of patients did not receive a further course of Lemtrada during the first year of the extension study, the company said.